AU2008281374B2 - Pharmaceutical composition for treating wounds and related methods - Google Patents

Pharmaceutical composition for treating wounds and related methods Download PDF

Info

Publication number
AU2008281374B2
AU2008281374B2 AU2008281374A AU2008281374A AU2008281374B2 AU 2008281374 B2 AU2008281374 B2 AU 2008281374B2 AU 2008281374 A AU2008281374 A AU 2008281374A AU 2008281374 A AU2008281374 A AU 2008281374A AU 2008281374 B2 AU2008281374 B2 AU 2008281374B2
Authority
AU
Australia
Prior art keywords
seq
insulin
composition
alpha
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008281374A
Other languages
English (en)
Other versions
AU2008281374A1 (en
Inventor
Liora Braiman-Wiksman
Ephraim Brener
Ofra Levy-Hacham
Inessa Solomonik
Tamar Tennenbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Healor Ltd
Original Assignee
Healor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healor Ltd filed Critical Healor Ltd
Publication of AU2008281374A1 publication Critical patent/AU2008281374A1/en
Application granted granted Critical
Publication of AU2008281374B2 publication Critical patent/AU2008281374B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2008281374A 2007-07-30 2008-07-30 Pharmaceutical composition for treating wounds and related methods Ceased AU2008281374B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96270607P 2007-07-30 2007-07-30
US60/962,706 2007-07-30
PCT/IL2008/001049 WO2009016629A2 (en) 2007-07-30 2008-07-30 Pharmaceutical composition for treating wounds and related methods

Publications (2)

Publication Number Publication Date
AU2008281374A1 AU2008281374A1 (en) 2009-02-05
AU2008281374B2 true AU2008281374B2 (en) 2012-05-31

Family

ID=40305016

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008281374A Ceased AU2008281374B2 (en) 2007-07-30 2008-07-30 Pharmaceutical composition for treating wounds and related methods

Country Status (10)

Country Link
US (3) US20100310542A1 (https=)
EP (2) EP2185184A2 (https=)
JP (3) JP5411857B2 (https=)
KR (2) KR20130121678A (https=)
CN (2) CN102755649A (https=)
AU (1) AU2008281374B2 (https=)
CA (1) CA2694927A1 (https=)
NZ (1) NZ582556A (https=)
RU (2) RU2502520C2 (https=)
WO (1) WO2009016629A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013885A2 (en) 2003-08-07 2005-02-17 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
EP2452686A3 (en) * 2005-08-29 2012-09-05 HealOr Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
WO2011011808A1 (en) * 2009-07-30 2011-02-03 Roman Buga A cosmetic composition comprising sodium chloride in combination with one or more of protein, collagen, gelatin or amino acid
US8889615B2 (en) 2009-12-31 2014-11-18 New York University Methods for promoting epithelialization and healing of chronic wounds
EP2523677A2 (en) * 2010-01-11 2012-11-21 Healor Ltd. Method for treatment of inflammatory disease and disorder
AU2011327785A1 (en) * 2010-11-08 2013-03-07 Healor Ltd. Buffered ophthalmic compositions and methods of use thereof
US10342891B2 (en) * 2013-09-19 2019-07-09 Medline Industries, Inc. Wound dressing containing saccharide and collagen
EP3501531A1 (en) 2014-01-29 2019-06-26 Université de Strasbourg New target for diabetes treatment and prevention
EP3421485A1 (en) 2017-06-30 2019-01-02 Université de Strasbourg Peptides for treatment and prevention of hyperglycaemia
RU2766292C1 (ru) * 2021-08-05 2022-03-14 Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства (ФГУП СПбНИИВС ФМБА России) Состав вакцины против covid-19

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002009639A2 (en) * 2000-07-31 2002-02-07 Bar Ilan University Methods and pharmaceutical compositions for healing wounds
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
WO2007026356A2 (en) * 2005-08-29 2007-03-08 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549747A (en) * 1968-02-20 1970-12-22 Flow Pharma Inc Contact lens wetting solution and method of using same
US3947573A (en) * 1969-12-01 1976-03-30 Burton, Parsons And Company, Inc. Opthalmic solution
US3856919A (en) * 1970-06-08 1974-12-24 Burton Parsons Chemicals Inc Ophthalmic solution
US3767788A (en) * 1970-06-08 1973-10-23 Burton Parsons Chemicals Inc Ophthalmic solution
US3767789A (en) * 1971-06-21 1973-10-23 Burton Parsons & Co Inc Method of providing a synthetic mucus in vivo
US3987163A (en) * 1973-07-27 1976-10-19 Burton, Parsons And Company, Inc. Polystyrene sulfonate containing opthalmic solutions
US3907985A (en) * 1973-07-27 1975-09-23 Burton Parsons And Company Inc Polystyrene sulfonate containing opthalmic solutions
US4029817A (en) * 1973-09-24 1977-06-14 Allergan Pharmaceuticals Soft contact lens preserving solutions
US3920810A (en) * 1974-04-23 1975-11-18 Burton Parsons And Company Inc Polyacrylamide containing ophthalmic solutions
US4120949A (en) * 1977-10-05 1978-10-17 Cooper Laboratories, Inc. Ophthalmic solution
US4131651A (en) * 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4558033A (en) * 1983-06-06 1985-12-10 Amgen Potentiation of the effects of insulin by peptides
US4673649A (en) * 1983-07-15 1987-06-16 University Patents, Inc. Process and defined medium for growth of human epidermal keratinocyte cells
DE3674883D1 (de) * 1985-11-25 1990-11-15 Wako Pure Chem Ind Ltd Farbentwicklungsmethode in klinischen untersuchungen.
US4801612A (en) * 1986-07-03 1989-01-31 Regents Of The University Of California Method of inhibiting inflammatory response
US4833257A (en) * 1986-07-28 1989-05-23 Arizona Board Of Regents Compositions of matter and methods of using same
IL80298A (en) * 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
JPH0739508B2 (ja) * 1986-11-11 1995-05-01 株式会社林原生物化学研究所 プルラン・ポリエチレングリコ−ル会合物とその製造方法並びに用途
US4808402A (en) * 1987-05-29 1989-02-28 Northwestern University Method and compositions for modulating neovascularization
US5137734A (en) * 1989-03-22 1992-08-11 Dana Farber Cancer Institute Angiogenic monoglycerides
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5158935A (en) * 1989-05-12 1992-10-27 Chiron Corporation Human epidermal growth factor having substitution at position 11
US5723119A (en) * 1989-07-28 1998-03-03 Schering Corporation Method for enhancing wound healing/repair with IL-4
US5145679A (en) * 1989-10-05 1992-09-08 Hinson Joan B Topical emollient for prevention and treatment of circulatory induced lesions
US5981606A (en) * 1991-03-01 1999-11-09 Warner-Lambert Company Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same
AU668509B2 (en) * 1991-04-19 1996-05-09 Affinity Biotech, Inc. Convertible microemulsion formulations
HUT67319A (en) * 1991-08-30 1995-03-28 Life Medical Sciences Inc Compositions for treating wounds
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
AU3062392A (en) * 1991-11-04 1993-06-07 Novo Nordisk A/S Pdgf gel formulation
US6537973B1 (en) * 1992-03-16 2003-03-25 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US5922686A (en) * 1992-03-16 1999-07-13 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of protein kinase C
DE4208552A1 (de) * 1992-03-17 1993-09-23 Liedtke Pharmed Gmbh Topische arzneiformen mit insulin
GB9210574D0 (en) * 1992-05-18 1992-07-01 Ca Nat Research Council Biotherapeutic cell-coated microspheres for wound/burn and prothesis implant applications
CA2125060C (en) * 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
US6028118A (en) * 1996-08-08 2000-02-22 Les Laboratoires Aeterna Inc. Methods of using extracts of shark cartilage
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
US5631245A (en) * 1995-06-06 1997-05-20 Biodynamics Pharmaceuticals, Inc. Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions
GB2304047A (en) * 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
DK0877752T3 (da) * 1996-01-23 2003-09-15 Univ Leland Stanford Junior Fremgangsmåder til screening af transdominante effektorpeptider og RNA molekyler
US5869037A (en) * 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes
JPH10158188A (ja) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd 角膜治療用組成物
GB9702943D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Wound healing
US6274712B1 (en) * 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
FR2773075B1 (fr) * 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
WO1999034821A1 (en) * 1998-01-09 1999-07-15 Novo Nordisk A/S Stabilised insulin compositions
US6790207B2 (en) * 1998-06-04 2004-09-14 Curon Medical, Inc. Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract
US6489306B2 (en) * 1998-02-23 2002-12-03 University Of South Florida Method of intranasal gene transfer for protection against respiratory infection
DE19826628C1 (de) * 1998-06-17 2000-07-20 Werner Kern Intranasale Verwendung von Insulin bei Hirnleistungsstörungen
US6376467B1 (en) * 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain
IL141021A0 (en) * 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
US6096288A (en) * 1998-10-12 2000-08-01 Mobil Oil Corporation Synthesis of the cubic mesoporous molecular sieve MCM-48
WO2000030628A2 (en) * 1998-11-20 2000-06-02 Genentech, Inc. Method of inhibiting angiogenesis
US7261881B1 (en) * 1999-05-20 2007-08-28 Yale University Modulation of angiogenesis and wound healing
US6541447B1 (en) * 1999-09-01 2003-04-01 B & M Healthcare Technologies, Inc. Wound healing composition and method for use thereof
NZ521437A (en) * 2000-02-25 2004-04-30 Immunex Corp Integrin antagonists suitable as inhibitors of angiogenesis
IL151833A0 (en) * 2000-03-24 2003-04-10 Novartis Ag Improved treatment of neovascularization
US6582713B2 (en) * 2000-04-06 2003-06-24 Univ. Of Colorado - Colorado Springs Compositions and methods for promoting wound healing
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
GB2369572A (en) * 2000-11-29 2002-06-05 Raft Trustees Ltd Wound treatment composition comprising insulin
US20020119914A1 (en) * 2000-12-26 2002-08-29 Deguang Zhu New uses of insulin and pancreatin
JP2002198443A (ja) * 2000-12-26 2002-07-12 Nec Corp 半導体装置及びその製造方法
GB0103877D0 (en) * 2001-02-16 2001-04-04 King S College London Novel Drug Delivery system
DE10109280A1 (de) * 2001-02-26 2002-09-05 Peter Mayser Indolderivate mit inhibitorischer Wirkung auf Proteinkinasen
KR100404072B1 (ko) * 2001-03-12 2003-11-03 주식회사 두산 광범위 피부질환 치료용 조성물
US20030091601A1 (en) * 2001-11-13 2003-05-15 Abat Inc. Use of topical arginine to enhance wound healing
US20030124503A1 (en) * 2001-12-28 2003-07-03 Olivencia-Yurvati Albert H. Pyruvate cardioplegia solutions for administration to the heart during cardiopulmonary surgery and methods of use thereof
WO2003059396A1 (en) * 2002-01-11 2003-07-24 Sergei Zolotukhin Adiponectin gene therapy
RU2249467C2 (ru) * 2002-11-25 2005-04-10 ООО Научно-производственное предприятие "ЭРЛОН", Лтд. Медицинский материал и изделия на его основе
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
SE0300207D0 (sv) * 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
US7190893B2 (en) * 2003-06-27 2007-03-13 Valeo Electrical Systems, Inc. Fluid heater with low porosity thermal mass
NZ588743A (en) * 2003-07-15 2012-05-25 Univ Bar Ilan Use of a protein kinase C (PKC) alpha inhibitor for treating inflammation of the skin
WO2005013885A2 (en) * 2003-08-07 2005-02-17 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
US20050164323A1 (en) * 2003-12-24 2005-07-28 Wyeth Methods of treating asthma
US7902330B2 (en) * 2004-02-13 2011-03-08 Albert Einstein College Of Medicine Of Yeshiva University Protein kinase inhibitors and methods for identifying same
EP1877424A4 (en) * 2005-04-11 2010-09-29 Pharmagap Inc INHIBITORS OF PROTEIN KINASES AND USES THEREOF
WO2007016777A1 (en) * 2005-08-05 2007-02-15 Pharmagap Inc. Targeted protein kinase c inhibitors and uses thereof
EP1931327B1 (en) * 2005-08-19 2016-08-17 Emisphere Technologies, Inc. Cyclopropyl compounds and compositions for delivering active agents
US20090306045A1 (en) * 2005-12-22 2009-12-10 Ira Mellman Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease
US20080292726A1 (en) * 2007-01-23 2008-11-27 Bernstein Lawrence R Ophthalmic gallium compositions and methods of their use
US20110223177A1 (en) * 2008-09-09 2011-09-15 University Of East Anglia Treatment of fibrotic eye disorders
CA2751156A1 (en) * 2009-02-24 2010-09-02 Healor Ltd. Visfatin therapeutic agents for the treatment of acne and other conditions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002009639A2 (en) * 2000-07-31 2002-02-07 Bar Ilan University Methods and pharmaceutical compositions for healing wounds
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
WO2007026356A2 (en) * 2005-08-29 2007-03-08 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Carcinogenesis, 1996, 17(6): 1259-1265 *
Cell Growth & Differen, 1993, 4(4): 309-316 *
Diabetes, 2001, 55: 255-264 *
J Trauma, Injury, Infection & Critical Care, 1998, 44(2): 342-345 *

Also Published As

Publication number Publication date
US20100310542A1 (en) 2010-12-09
WO2009016629A3 (en) 2009-05-22
CN101835486B (zh) 2012-12-12
EP2185184A2 (en) 2010-05-19
JP2014024862A (ja) 2014-02-06
EP2653166A2 (en) 2013-10-23
US20140227243A1 (en) 2014-08-14
AU2008281374A1 (en) 2009-02-05
CN101835486A (zh) 2010-09-15
RU2502520C2 (ru) 2013-12-27
RU2013142159A (ru) 2015-03-27
HK1148467A1 (en) 2011-09-09
US20130336952A1 (en) 2013-12-19
NZ582556A (en) 2013-02-22
JP2010535194A (ja) 2010-11-18
KR20100040912A (ko) 2010-04-21
KR20130121678A (ko) 2013-11-06
JP5411857B2 (ja) 2014-02-12
WO2009016629A2 (en) 2009-02-05
CN102755649A (zh) 2012-10-31
JP2013144697A (ja) 2013-07-25
RU2010106661A (ru) 2011-09-10
EP2653166A3 (en) 2014-08-27
CA2694927A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
AU2008281374B2 (en) Pharmaceutical composition for treating wounds and related methods
KR102588702B1 (ko) 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해
Takano et al. Oxidative stress-induced signal transduction pathways in cardiac myocytes: involvement of ROS in heart diseases
EP2152294B1 (en) A bad bh3 domain peptide for use in treating or delaying the onset of diabetes.
Gold et al. Overview of the role for calreticulin in the enhancement of wound healing through multiple biological effects
JP2009506107A (ja) 糖尿病および皮膚の老化を予防および治療するための方法および組成物
KR20080050497A (ko) Ｃｄ36 발현을 감소시키는 방법
US20060258562A1 (en) Methods and pharmaceutical compositions for healing wounds
Zorina et al. Prospects for the use of intranasally administered insulin and insulin-like growth factor-1 in cerebral ischemia
Wang et al. Fibroblast growth factor 21 improves glucose homeostasis partially via down-regulation of Na+-d-glucose cotransporter SGLT1 in the small intestine
WO2010027802A2 (en) Methods for treating diabetic wounds
Zheng et al. Tartrate resistant acid phosphatase activity in rat cultured osteoclasts is inhibited by a carboxyl terminal peptide (osteostatin) from parathyroid hormone‐related protein
CA2823372A1 (en) Pharmaceutical composition for treating wounds and related methods
CN116194143A (zh) 中性粒细胞驱动的炎症性病理的治疗方法
HK1148467B (en) Pharmaceutical composition for treating wounds and related methods
US7157439B2 (en) HoxD3, HoxA3, and HoxB3 compositions and methods for improved wound healing
HK1172249A (en) Pharmaceutical composition for treating wounds and related methods
Zhang et al. Ghrelin promotes chronic diabetic wound healing by regulating keratinocyte proliferation and migration through the ERK1/2 pathway
Zhu et al. Inhibition of protein kinase C promotes neuronal survival in low potassium through an Akt-dependent pathway
US7115582B2 (en) HoxD3 and HoxA3 compositions and methods for improved wound healing
US20100247512A1 (en) Pericellular Collagenase Directs the 3-Dimensional Development of White Adipose Tissue
Crist et al. Effects of adenosine receptor antagonism on protein tyrosine phosphatase in rat skeletal muscle
US7544670B2 (en) HoxD3, HoxA3 and HoxB3 compositions and methods for improved wound healing
Nakata et al. Insulin stimulates placental leucine aminopeptidase/oxytocinase/insulin-regulated membrane aminopeptidase expression in BeWo choriocarcinoma cells
Singh et al. signalling in the mammalian myocardium

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired